Advanced native-kidney carcinoma in a heart- and kidney-transplanted patient: a case report
- 34 Downloads
Malignancies are one of the leading causes of death in long-term surviving transplant recipients. Dose and prolonged durations of immunosuppressive regimens are considered the main cause, through a direct oncogenic effect and a renowned interaction on physiological anti-viral and anti-oncogenic immune response. Specific neoplasms are known to occur with different frequencies according to the transplanted organ. As a consequence, imaging screenings have been implemented in many graft surveillance programs, although a wide consensus on the timing and modality has not been concurred. There are little data available in the literature regarding incidence of de-novo malignancies in multi-organ recipients. We report the case of a 66-year-old man who developed a renal mass 10 years after a combined heart–kidney transplant.
KeywordsCancer screening Immunosuppression Kidney transplantation Heart transplantation Post-transplant malignancy
Compliance with ethical standards
Conflict of interest
All the authors have declared no competing interests.
Human participants and animal rights statement
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent was obtained from the patient included in this article.
- 1.Tsai H, Lee C, Kuo C, et al. De novo malignancy in organ transplant recipients in Taiwan : a nationwide cohort population study. Oncotarget. 2017;8(22):36685–95.Google Scholar
- 6.Campistol JM. Minimizing the risk of posttransplant malignancy. Transpl Proc. 2008;40:27–30. https://doi.org/10.1016/j.transproceed.2008.10.015.CrossRefGoogle Scholar
- 11.Végsö G, Toronyi É, Hajdu M, et al. Renal cell carcinoma of the native kidney: a frequent tumor after kidney transplantation with favorable prognosis in case of early diagnosis. Transpl Proc. 2011;43:1261–3. https://doi.org/10.1016/j.transproceed.2011.03.068.CrossRefGoogle Scholar
- 12.Kälble T, Lucan M, Nicita G, Sells R, Burgos Revilla FJ, Wiesel M. EAU guidelines on renal transplantation. Eur Urol. 2005;47(2):156–66.Google Scholar
- 15.Sánchez-Lázaro IJ, Almenar-Bonet L, Martínez-Dolz L, et al. Post-heart transplant tumors: chronology and impact on survival. Transpl Proc. 2010;42:3201–3. https://doi.org/10.1016/j.transproceed.2010.05.052.CrossRefGoogle Scholar
- 16.Almenar-Bonet L. Spanish heart transplantation registry. 18th official report of the Spanish society of cardiology working group on heart failure, heart transplantation and associated therapies (1984–2006). Rev Española Cardiol (English Ed). 2007;60:1177–87.Google Scholar
- 21.Awad M, Czer LSC, Esmailian F, et al. Combined heart and kidney transplantation: a 23-year experience. Transpl Proc. 2017;49:348–53. https://doi.org/10.1016/j.transproceed.2016.11.040.CrossRefGoogle Scholar
- 22.López-Sainz A, Barge-Caballero E, Paniagua-Martin MJ, et al. Clinical characteristics and long-term outcomes of patients undergoing combined heart-kidney transplantation: a single-center experience. Transpl Proc. 2015;47:123–6. https://doi.org/10.1016/j.transproceed.2014.11.009.CrossRefGoogle Scholar
- 24.Hevia V, Gomez V, Diez Nicolas V, et al. Development of urologic de novo malignancies after renal transplantation. Transpl Proc. 2014;46:170–5. https://doi.org/10.1016/j.transproceed.2013.12.004.CrossRefGoogle Scholar
- 29.Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transpl 2009, 9(Suppl 3), pp. S1–155. https://doi.org/10.1111/j.1600-6143.2009.02834.x.